Cesium-131 From IsoRay Medical, Inc. Established as a Front Line Treatment for Early Stage Prostate Cancer Treatment in a Recent Clinical Trial

CHICAGO--(BUSINESS WIRE)--Investigators of a recent multi-institutional trial, led by principal investigator Bradley Prestidge, conclude that Cesium-131, a medical isotope used in low dose (LDR) brachytherapy treatment for prostate cancer, “… has come into widespread use; and the clinical results of this trial are mature enough to be of immediate, important, practical use to practitioners.”